US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust SMID Growth Strength ETF

29.06

0.0000

Post-market: 29.060.00000.00%16:10 EDT

Volume:20.00

Turnover:572.43

Market Cap:27.61M

PE:- -

High:29.06

Open:29.06

Low:29.06

Close:29.06

52wk High:31.95

52wk Low:24.39

Shares:950.00K

Float Shares:950.00K

Volume Ratio:0.03

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Dimerix Over-Recruits in Pivotal FSGS Phase 3 Trial as Last Adult Patient Dosed

Dimerix Courts Investors With Perth and Singapore Briefings on FSGS Phase 3 Program

Dimerix to Showcase Phase 3 FSGS Program at Oppenheimer Healthcare Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/FSGS"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FSGS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","market":"US","secType":"STK","nameCN":"First Trust SMID Growth Strength ETF","latestPrice":29.0603,"timestamp":1774641600000,"preClose":29.0603,"halted":0,"volume":20,"hourTrading":{"tag":"盘后","latestPrice":29.0603,"preClose":29.0603,"latestTime":"16:10 EDT","volume":7,"amount":199.3705,"timestamp":1774642204822,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":950002,"shares":950002,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"03-27 16:00:00 EDT","open":29.0603,"high":29.0603,"low":29.0603,"amount":572.4308,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":29.0603,"sharesOutstanding":950002,"nav":29.07,"aum":27616558.14,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":29.0603,"preClose":29.0603,"latestTime":"16:10 EDT","volume":7,"amount":199.3705,"timestamp":1774642204822,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.02741980310826501},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","floatShares":950002,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.02741980310826501,"shares":950002,"dividePrice":0,"high":29.0603,"amplitude":0,"preClose":29.0603,"low":29.0603,"week52Low":24.39,"pbRate":"--","week52High":31.95,"institutionHeld":0,"latestPrice":29.0603,"eps":0,"divideRate":0,"volume":20,"delay":0,"ttmEps":0,"open":29.0603,"prevYearClose":30.4325,"prevWeekClose":29.4033,"prevMonthClose":30.6815,"prevQuarterClose":30.4325,"fiveDayClose":29.4033,"twentyDayClose":30.6815,"sixtyDayClose":30.7389},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FSGS\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FSGS","amount":0.3931,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"FIRST TRUST EXCHANGE-TRADED FUND VI FIRST TRUST SMID GROWTH STRENGTH ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FSGS\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":0.3931,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FSGS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FSGS\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622027703","title":"Press Release: Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2622027703","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622027703?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436400,"startTime":"0","endTime":"0","summary":"Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT. Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026. Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors. Strong balance sheet with $360.0 million in cash, cash equivalents and marketable securities; expected cash runway into 2028. \"We are proud of the progress that Maze achieved in 2025 and have already carried our strong record of execution into the new year, as evidenced by today's positive topline data from our Phase 2 HORIZON trial of MZE829 in broad AMKD,\" said Jason Coloma, Ph.D., chief executive officer of Maze. \"We look forward to advancing MZE829 into a pivotal program and to initiating our two Phase 2 trials of MZE782 in PKU and CKD. As we continu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIT","BK4604","FSGS","BK4099","BK4555","BK4585","BK4588","MAZE","TM","BK4007","03160"],"gpt_icon":0},{"id":"2618505608","title":"Dimerix Over-Recruits in Pivotal FSGS Phase 3 Trial as Last Adult Patient Dosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2618505608","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618505608?lang=en_us&edition=fundamental","pubTime":"2026-03-10 06:38","pubTimestamp":1773095926,"startTime":"0","endTime":"0","summary":"Dimerix Limited ( ($AU:DXB) ) has issued an update. Dimerix has completed enrolment and first dosing of the last adult patient in its pivotal ACTIO...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dimerix-over-recruits-in-pivotal-fsgs-phase-3-trial-as-last-adult-patient-dosed?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dimerix-over-recruits-in-pivotal-fsgs-phase-3-trial-as-last-adult-patient-dosed?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FSGS"],"gpt_icon":0},{"id":"2616085653","title":"Dimerix Courts Investors With Perth and Singapore Briefings on FSGS Phase 3 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2616085653","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616085653?lang=en_us&edition=fundamental","pubTime":"2026-03-04 07:17","pubTimestamp":1772579845,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Dimerix Limited ( ($AU:DXB) ). Dimerix Limited has invited existing and potential investors to attend interacti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dimerix-courts-investors-with-perth-and-singapore-briefings-on-fsgs-phase-3-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dimerix-courts-investors-with-perth-and-singapore-briefings-on-fsgs-phase-3-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FSGS","BK4211","ISBC"],"gpt_icon":0},{"id":"2614005272","title":"Dimerix to Showcase Phase 3 FSGS Program at Oppenheimer Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2614005272","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614005272?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:54","pubTimestamp":1772153679,"startTime":"0","endTime":"0","summary":"Dimerix Limited ( ($AU:DXB) ) has issued an announcement. Dimerix Limited will present an update on its Phase 3 ACTION3 trial of DMX-200 for FSGS k...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dimerix-to-showcase-phase-3-fsgs-program-at-oppenheimer-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dimerix-to-showcase-phase-3-fsgs-program-at-oppenheimer-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","OPY","HCSG","BK4588","BK4137","LU0128526141.USD","LU0029874061.USD","FSGS","BK4581","BK4585","LABU","BK4127","XLV"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/FSGS\",params:#limit:6,delay:false,,,undefined,":[]}}